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Abstract Occurrence of autoantibodies (autoAbs) is a hall-
mark of autoimmune diseases, and the analysis thereof is an
essential part in the diagnosis of organ-specific autoimmune
and systemic autoimmune rheumatic diseases (SARD), espe-
cially connective tissue diseases (CTDs). Due to the appear-
ance of autoAb profiles in SARD patients and the complexity
of the corresponding serological diagnosis, different diagnos-
tic strategies have been suggested for appropriate autoAb test-
ing. Thus, evolving assay techniques and the continuous dis-
covery of novel autoantigens have greatly influenced the de-
velopment of these strategies. Antinuclear antibody (ANA)
analysis by indirect immunofluorescence (IIF) on tissue and
later cellular substrates was one of the first tests introduced
into clinical routine and is still an indispensable tool for CTD
serology. Thus, screening for ANA by IIF is recommended to
be followed by confirmatory testing of positive findings
employing different assay techniques. Given the continuous
growth in the demand for autoAb testing, IIF has been chal-
lenged as the standard method for ANA and other autoAb
analyses due to lacking automation, standardization, modern
data management, and human bias in IIF pattern interpreta-
tion. To address these limitations of autoAb testing, the
CytoBead® technique has been introduced recently which en-
ables automated interpretation of cell-based IIF and quantita-
tive autoAb multiplexing by addressable microbead immuno-
assays in one reaction environment. Thus, autoAb screening
and confirmatory testing can be combined for the first time.
The present review discusses the history of autoAb assay tech-
niques in this context and gives an overview and outlook of
the recent progress in emerging technologies.
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Autoantibodies as Diagnostic Markers
Connective Tissue Disease-Specific Autoantibodies
The loss of immune tolerance characteristic for connective
tissue diseases (CTDs) such as systemic lupus erythematosus
(SLE), systemic sclerosis (SSc), poly/dermatomyositis (PM/
DM), Sjögren’s syndrome (SjS), and mixed connective tissue
disease (MCTD) brings about the generation of various
nonorgan-specific autoantibodies (autoAbs) [1–3]. Although
the triggering factors for the occurrence of autoAbs and their
role in the pathogenesis of CTD are still not entirely under-
stood, autoAbs are widely used as diagnostic markers in clin-
ical routine nowadays [4, 5]. The L.E. cell phenomenon de-
scribed by Hargraves in the late 1940 in patients suffering
from SLE proved to be a result of autoAb binding to nuclear
material of polymorphs and marked the beginning of a rapidly
evolving autoAb era in clinical diagnostics [6]. Indirect im-
munofluorescence (IIF) was the first assay technique
employed to reveal autoAbs in patients with CTD [7]. The
groundbreaking works of Holborow and Friou et al. led to
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the discovery of so-called antinuclear antibodies (ANAs) as
marker autoAbs of CTD like SLE [8, 9]. In the following
years, clinicians made tremendous efforts to understand the
clinical significance of autoAbs and their potential use for
the serological diagnosis of CTD and beyond [10]. This pro-
cess was greatly driven by novel emerging assay techniques
used for autoAb testing and their respective assay perfor-
mance characteristics (Fig. 1; Table 1). The ensuing discourse
has led to the definition of various diagnostic strategies for the
serological diagnosis of autoimmune disorders and continues
to date. Of note, ANA detected by IIF was included into the
diagnostic criteria of SLE and autoimmune hepatitis (AIH)
later [11–13]. In this context, the discovery of autoAbs to
extractable nuclear antigens (ENAs) apart from autoAbs to
dsDNA or histones in the search for disease-specific
autoAbs provides an intriguing example for the change in
the understanding of the clinical meaning of autoAbs as diag-
nostic markers [14–16]. Thus, the seminal paper of E.M. Tan
and H.G. Kunkel on the identification of Sm as an
autoantigenic target of SLE and the use of double radial im-
munodiffusion (DRID; Ouchterlony technique) for its detec-
tion ushered in a new era in autoAb diagnostics and its clinical
application [17]. Although ANA turned out to be a sensitive
marker for SARD as a whole disease group, its specificity for
distinct SARD entities was not satisfactory despite being de-
fined as a diagnostic marker for SLE [11]. Thus, the clinical
need for more specific BANA^ was met by the pioneering
work of H.G. Kunkel, E.M. Tan, and others discovering more
and more novel autoAbs to ENA with clinical significance
[14, 18]. However, not all ENAs identified as targets for
CTD-specific autoAbs could be isolated by the saline extrac-
tion technique reported previously and should not be termed
ENA [19]. Furthermore, apart from autoAbs recognizing nu-
clear autoantigens, anticytoplasmic autoAbs (ACyA) have
been introduced into the autoAb panel for SARD serology
[20]. Thus, the anti-SjS antigen A (SS-A) autoAbs also termed
Ro have been shown to interact with its respective target in the
cytoplasm [21]. As a fact, the progress in proteomics enabled
the identification of cytoplasmic autoantigenic targets
interacting with for instance myositis-specific autoAbs like
anti-histidyl tRNAse autoAbs (Jo-1) or SLE specific autoAb
against ribosomal proteins [22–24]. Obviously, this created
confusion among clinical and laboratory experts and called
for clarification. In terms of ANA testing, the introduction of
human epidermoid laryngeal carcinoma (HEp-2) cells as im-
proved autoantigenic substrate in IIF has encouraged the
reporting of CTD-specific cytoplasmic patterns over the years
[2]. This contradiction in terminology was addressed by a
recent consensus recommending the use of anticellular anti-
bodies instead of ANA [4]. Notwithstanding, the use of ANA
and ENA is well established particularly among clinicians and
it remains to be seen how this issue will be solved adequately
in the years to come [25]. In summary, autoAb testing is an
integral part in the serological diagnosis of CTD and may also
assist in the prognosis, subclassification, as well as monitoring
of disease activity [4, 10, 26–29].
As mentioned earlier, not only the discovery of novel
SARD-specific autoAbs has challenged the diagnostic skills
of clinicians but the introduction of novel assay techniques
with differing assay performance, too [30]. Thus, the change
from immunodiffusion-based detection techniques like DRID
or counterimmunoelectrophoresis (CIE) detecting precipitat-
ing autoAbs to enzyme-linked immunosorbent assay (ELISA)
regarding the analysis of autoAbs to Sm or SS-A called the
specificity of these distinct markers suddenly into question
[31–33]. The solid-phase ELISA brought about a significantly
elevated sensitivity which in turn is related to a diminished
diagnostic specificity [34]. Furthermore, with the better under-
standing of the chemical structure of for instance the small
nuclear ribonucleoprotein (snRNP) complex representing the
Sm autoantigen, six different protein structures (B, B’, D, E, F,
G) were identified as autoantigenic targets with SmD being
apparently the most specific one for SLE [35–37]. Alone,
these critical aspects require a comprehensive knowledge on
Fig. 1 Evolving autoantibody (autoAb) testing and strategies for the
serological diagnosis of systemic autoimmune rheumatic diseases. ANA
a n t i n u c l e a r a n t i b o d y , a u t o A b a u t o a n t i b o d y , C I E
counterimmunoelectrophoresis, D/LIA dot/line immunoassay, ELISA
enzyme-linked immunosorbent assay, ENA extractable nuclear antigen,
IB immunoblot/westernblot, ID/DRID immunodiffusion/double radial
immunodi f fus ion , I IF ind i rec t immunof luorescence , IP
immunoprecipi ta t ion, MIA microbead immunoassay, RIP
radioimmunoprecipitation
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Table 1 Autoantibody (AAB) detection methods in routine diagnostics of systemic rheumatic diseases
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the interpretation of assay characteristics by clinicians which
were not always conveyed by laboratorians adequately [1, 3].
The badly needed comprehension of pretest and posttest prob-
abilities of presence of disease and its relation to the diagnostic
performance of autoAb analysis such as ANA testing appears
not satisfactorily developed in clinicians [19, 38, 39]. Thus,
novel diagnostic strategies translating the progress in autoAb
testing proved difficult to get in line with established diagnos-
tic pathways [27, 40, 41]. The recent attempt to substitute
ANA IIF testing as screening assay within the two-tier strate-
gy by novel multiplex techniques failed or met with great
resistance among rheumatologists [4, 42, 43]. Consequently,
the two-stage strategy recommending ANA testing by IIF as
screening and appropriate confirmation of ANA positives by a
different analysis was confirmed by expert consensus for CTD
serology recently [4].
Autoimmune Vasculitis-Specific Autoantibodies
Of note, like revealed for the L.E. phenomenon in patients
with SLE, patients suffering from autoimmune vasculitides
demonstrate loss of tolerance to polymorphs, too [44]. In con-
trast, the occurring autoAbs recognize specific neutrophil cy-
toplasmic and not nonspecific nuclear components and were
Table 1 (continued)
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ANA antinuclear antibody, autoAb autoantibody, CCP cyclic citrulinated peptide, CTD connected tissue disease, DIA/LIA dot/line immunoassay, ELISA
enzyme-linked immunosorbent assay, ENA extractable nuclear antigen, IIF indirect immunofluorescence, RF rheumatoid factor, SARD systemic
autoimmune disease, SLE systemic lupus erythematosus, SSc systemic sclerosis
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described first in association with glomerulonephritis in 1982
byDavies et al. [45]. Van deWoude’s group reported so-called
antineutrophil cytoplasmic antibodies (ANCAs) to be associ-
ated with granulomatosis with polyangiitis (GPA, formerly
Wegener’s granulomatosis) shortly later and, consequently,
the term ANCA-associated vasculitides (AAV) was coined
[44, 46, 47]. Thus, this group of autoimmune vascular disor-
ders comprises GPA, microscopic polyangiitis (MPA), and
eosinophilic granulomatosis with polyangiitis (EGPA, former-
ly Churg-Strauss syndrome) [48, 49]. Their leading clinical
characteristics are microvascular inflammation, tissue necro-
sis, and the appearance of ANCAs [50].
Interestingly, similar to ANA testing, IIF was the first
method to be used for the detection of ANCA revealing two
major patterns, cytoplasmic (cANCA) and perinuclear ANCA
(pANCA) [45, 51]. Not surprisingly, the respective main
autoantigenic neutrophilic targets, proteinase 3 (PR3), and
myeloperoxidase (MPO) were discovered shortly afterward
[52, 53]. Consequently, a two-stage strategy for ANCA testing
highlighting IIF as a standard method is recommended by
international consensus for the serology of AAV, too [54].
Indeed, the unsurpassed high sensitivity of autoAb analysis
employing cellular substrates by IIF renders this method an
ideal tool for the screening stage followed by confirmatory
testing with different immunological assay technologies
[47]. However, similar to ANA IIF reading, interpretation of
ANCA patterns is rather time consuming due to lack of auto-
mation and skilled laboratory experts [55]. Thus, IIF is in
general highly subjective what renders appropriate standardi-
zation difficult [56, 57]. Therefore, attempts to replace IIF by
novel techniques based on solid-phase immunoassays (e.g.,
ELISA, dot/line immunoassay, addressable bead/microarray
assays) for ANCA as well as ANA analyses are increasing
currently [58–62]. Indeed, in contrast to IIF, these assay tech-
niques can be automated and proved to be more cost-efficient
in the modern laboratory environment characterized by a ris-
ing diagnostic demand due to the growing clinical impact of
autoimmune diseases. However, worrying rates of false-
negative findings have been reported for these techniques in
terms of ANA as well as ANCA testing [42]. Of note, this fact
also appears to be relevant for organ-specific autoimmune
disorders like celiac disease (CD).
Celiac Disease-Specific (Auto)Antibodies
Celiac disease, a gluten-related and immune-mediated small
intestinal disease, is one of the few autoimmune disorders
which the triggering factor was identified for [63]. Indeed,
gliadin peptides deamidated by tissue transglutaminase type
2 (TG2) were shown as gluten-related T-cell epitopes trigger-
ing chronic inflammatory intestinal lesions and leading to vil-
lous atrophy and hyperplasia of the crypts [64].
Like for CTD and AAV, serology is paramount for the
diagnosis of CD encompassing the detection of (auto)Abs to
endomysium (EmA), deamidated gliadin peptides (DGP), and
TG2 of the IgA isotype [65]. As a fact, due to the excellent
assay performance of EmA testing by IIF, this particular
autoAb is still considered the reference standard for CD-
specific (auto)Abs [65–67]. However, similar to ANA and
ANCA testing by IIF, EmA IIF analysis was questioned more
and more because it may be subject to interobserver as well as
substrate-related variability and is difficult to automate [68].
Obviously, testing of anti-TG2 autoAbs by immunometric
solid-phase assays was favored instead [69–72].
In summary, IIF as one of the first techniques employed for
autoAb testing in various autoimmune disease diagnostics ap-
pears to keep its appeal with laboratorians and clinicians de-
spite several shortcomings [73, 74]. The integration of IIF as
screening or standard method for autoAb analysis into two-
stage or multiplex strategies was necessary as yet, but creates
cost constraints for health care systems already burdened with
spiraling costs. This calls for innovative solutions to meet the
growing demand for autoAb testing in clinical routine.
EvolvingAssay Techniques for Autoantibody Testing
Single Tests for autoAb Analysis
The introduction of fluorescent dyes and the development of
immunochemical methods for the labeling of antibodies on
the one hand and fluorescence microscopy on the other hand
paved the way for IIF as powerful tool for autoAb analysis in
the 1950s [75]. Thus, the detection of ANA by IIF employing
first rodent liver tissue and later HEp-2 cells as autoantigenic
substrate marks the beginning of autoAb detection in the se-
rological diagnosis of CTD [7, 9, 76, 77]. However, it turned
out soon that the clinical need for disease-specific autoAbs
was not appropriately addressed by ANA testing alone. The
search for more specific autoAbs led to the introduction of
immunodiffusion techniques which enabled the discovery of
disease-specific autoAbs like the Sm autoAb in patients suf-
fering from SLE [16, 17, 21]. In particular, DID employing
thymic extracts was used and clinicians learnt to appreciate the
high specificity of this new parameter for CTD serology. Not
surprisingly, autoAbs to Smwere included along with ANA in
the diagnostic criteria for SLE later and are still considered as
one of the most specific serological parameters for SLE
[11, 14]. However, DRID is a time-consuming technique
and, thus, was replaced by CIE enabling a faster and more
sensitive detection of precipitating autoAbs later on [31].
Several other important autoAbs to the spliceosomal complex
such as autoAbs to U1 ribonucleoprotein (U1-RNP) were
identified in the quest for new CTD markers [21]. Anti-U1-
RNP was established as a specific serological marker for
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MCTD and found in patients with SLE as well [78, 79]. The
introduction of new assay techniques like radio- (RIA) and
enzyme immunoassays as well as radio/immunoprecipitation
paved the way for the development of autoAb detection assays
with better assay performance [32, 62, 80–86]. In particular,
the progress in proteomics and the introduction of the immu-
noblot technique enabled the purification and identification of
the distinct autoantigenic targets [33, 87–89]. It turned out that
Sm and U1-RNP consist of several autoantigenic components
including U1-RNA with different characteristics regarding
their performance as split autoantigens especially in solid-
phase ELISAs [79, 90, 91]. Furthermore, the SjS-specific
autoantigens SS-A and SS-B form a complex interacting with
yRNA [92]. Of note, this confers only to the SS-A 60 kDa unit
whereas the 52 kDa SS-A (TRIM21) does not bind to yRNA
and is not related to this snRNP complex [93, 94]. This raised
the question of the best composition of these targets for the
detection of the distinct autoAbs or the use of the target sub-
component with the best assay performance [90]. In terms of
U1-RNP consisting of components A, C, and a 68 kDa poly-
peptide, it was found that at least two of these three should be
used as solid-phase antigens to set up an appropriate ELISA
for the detection of autoAbs to U1-RNP [19]. In contrast,
SmD of the Sm complex with its six subcomponents men-
tioned earlier appeared to be the most specific and sensitive
autoantigenic target in ELISA for the serology of SLE [14].
In general, the introduction of solid-phase assays like
ELISAwas accompanied by four major aspects changing the
understanding of autoAb testing for CTD diagnostics: (i) a
better usability as assay platform, (ii) an increasing sensitivity
compared with immunodiffusion techniques, (iii) the different
assay performance of autoAbs recognizing conformational or
nonconformational, linear epitopes, and (iv) the introduction
of reference sera for standardized diagnostics. This was an
essential step toward standardization and automation of
autoAb testing addressing the growing demand thereof due
to the inclusion of autoAb testing into diagnostic or classifi-
cation criteria of more and more autoimmune diseases and
changed the autoimmune laboratory environment dramatical-
ly [80, 95]. Consequently, assay techniques like IIF, which
have been prone to subjectivity and difficult to automate until
recently, were subjected to a rising pressure to be substituted
[73, 96, 97]. In this context, several researchers were tempted
by the advantages of the ELISA technique and in particular its
higher sensitivity to develop assays employing cellular ex-
tracts of MOLT4 or HEp-2 cells [98–101]. Furthermore, the
elevated sensitivity of particularly anti-SS-A ELISAs revealed
false-negative ANA sera of patients suffering from CTD
[102–105]. Indeed, this seems to be the only autoantigenic
target which is not adequately presented even by HEp-2 cells
and can result in false-negative ANA findings by IIF. To
overcome this shortcoming of the appreciated IIF tech-
nique, genetically modified HEp-2 cells with a higher
expression of the SS-A 60 kDA polypeptide were intro-
duced in ANA testing [103, 106].
Of note, the increased sensitivity of ELISA resulted in pos-
itive autoAb findings in nondiseased individuals, too, which
started an intense discourse on the right method for cutoff
determination [80]. Finally, receiver operating characteristics
curve analysis was approved for quantitative methods like
ELISA as the best approach to do so [39]. Part of the false-
positive findings could be assigned to autoAbs occurring be-
fore the onset of disease as putative predictive markers thereof
[29, 107]. Nonetheless, false-positive findings in ELISA
could be a result of autoAbs to less disease-specific
nonconformational epitopes [108]. These autoAbs often be-
long to the natural autoAb repertoire and display a low affinity
to its corresponding targets [109]. Avery convincing example
is the anti-double-stranded DNA (dsDNA) autoAb which was
established as diagnostic marker of SLE [110]. Of note, the
SLE-specific dsDNA epitope is ill-defined and IIF assays
employing kinetoplast dsDNA of Crithidia luciliae (CLIFT)
with its characteristic epitope structure appear to provide the
best specificity for this important disease activity-associated
SLE marker [108, 111–113]. The replacement of CLIFT and
the Farr RIA measuring mainly high-affinity anti-dsDNA
autoAbs due to a high-salt reaction environment by ELISAs
detecting autoAbs to both nonconformational and conforma-
tional dsDNA epitopes resulted in high numbers of false-
positives particularly in patients with infectious diseases [114].
A similar phenomenon was observed when recombinant or
synthetic autoantigens were introduced into autoAb testing to
overcome the difficulties related to antigen purification and
standardization [115, 116]. Not in each case, these nonnative
polypeptides could replace the native autoantigenic targets for
an appropriate autoAb analysis. Thus, the SmD polypeptide
was dependent on the symmetric methylation of arginine to
represent the SLE-specific epitope for the sensitive detection
of anti-Sm autoAbs [35, 36, 117]. Furthermore, the presence
of yRNA for the autoantigenicity of the SS-A/SS-B complex
on the one hand and of U1-RNA for the Sm/RNP unit on the
other hand was obviously required for the sensitive analysis of
the respective autoAbs [118, 119].
Remarkably, specific ANCA testing demonstrated similar
difficulties. Like for ANA testing, IIF was introduced as first
assay technique on fixed neutrophils [45]. However, the fol-
lowing identification of PR3 and MPO as the main ANCA
targets and the subsequent analysis of respective autoAbs by
ELISA were hampered by the nonsatisfactory sensitivity of
anti-PR3 autoAb tests [120–122]. Indeed, the conformational
epitopes on PR3 were difficult to preserve on the solid phases
of ELISAs. Recently, the third generation of PR3-ANCA
ELISA has been introduced employing anchor molecules
during adsorption of PR3 to the solid phase to preserve its
confirmation and accessibility of vasculitis-specific epitopes
[121, 122]. Other attempts to develop highly sensitive PR3-
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ANCA ELISAs comprised the use of a mixture of native as
well as recombinant PR3 [123].
The close relation between sensitivity and specificity is
presumably the reason that direct-ligand RIAs with their ex-
cellent sensitivity have not been used widely for the analysis
of CTD- or AAV-specific autoAbs. Interestingly, this is in
contrast to organ-specific autoimmune entities such as type 1
diabetes (T1D) where RIAs are appreciated hitherto due to
their high sensitivity [124, 125]. Of note, IIF on endocrine
pancreas had also been the first technique used for autoAb
analysis before the corresponding autoantigens were identi-
fied [126]. The detection of islet-cell autoAbs by IIF is still
in use; however, the impact of conformational epitopes for
T1D autoAbs testing in conjunction with the increased sensi-
tivity of RIAs and recently emerging ELISAs with similar
assay performances have almost replaced IIF [127].
After the discovery of TG2 as autoantigenic target of EmA
for CD serology, a similar development was observed in the
serological diagnosis of CD [128]. To obtain a sensitive anti-
TG2 autoAb assay, conformational epitopes of TG2 seem
to be essential, too [129]. In contrast to T1D autoAb test-
ing, however, the detection of EmA by IIF is still the gold
standard [65].
As a fact, the higher disease specificity of autoAbs to con-
formational epitopes is probably the reason for today’s infre-
quent use of immunoblot assays for autoAb serology [130].
Obviously, due to the poor presentation of such epitopes on
the blot membrane as a result of the denaturing effect of sodi-
um dodecyl sulfate during electrophoresis and the poor stan-
dardization of the method due to technical peculiarities, the
immunoblot technique has lost its initial appeal for multiplex
autoAb testing [89, 131].
Notwithstanding, due to the progress in the identification of
ever more autoAbs aiding in diagnosing, predicting and
prognosing autoimmune diseases, the search for the most ad-
equate strategy of autoAb testing fulfilling clinical needs and
cost constraints has been in the focus of laboratory and clinical
experts ever since [5, 59, 132–134]. For instance, more than
100 autoAbs were found in SLE patients alone [135]. This led
to the introduction of fully automated random-access instru-
ments employing fluorescence or chemiluminescence as read
out for autoAb testing as well as screening [136–139].
Remarkably, a two-stage strategy was recommended for
both ANA and ANCA analyses by international consensus
recommendations [4, 54]. Thus, IIF is still considered a reli-
able screening test characterized by a high negative predictive
value. Positive IIF findings should be confirmed by specific
autoAb testing employing assay techniques with high speci-
ficity. For several other autoimmune disorders like for in-
stance CD, IIF is still considered a gold standard [65]. Thus,
despite the introduction of assay techniques for the detection
of specific autoAb reactivities, there is still a need for testing
of autoAbs by various assay techniques.
Multiplex Assays for autoAb Testing
The rising number of autoAbs requested for the serology of
one autoimmune entity as well as the growing demand for
autoAb testing in general encouraged the development of mul-
tiplex testing [3, 140–142]. Despite the fact that ANA assess-
ment by IIF using HEp-2 cells as autoantigenic substrate is
already a multiplex test revealing different patterns according
to the autoAbs present in the serum investigated, the analysis
of specific autoAbs is hardly achievable [20, 96, 143, 144].
Even for such ready to detect ANA patterns like the centro-
mere one with its more than 40 fluorescent dots spread in
nuclei of interphase cells and densely aligned dots in the meta-
phase cells, several proteins could be recognized by autoAbs
as autoantigenic targets (centromere-associated proteins A, B,
and C) [57, 76, 145–147].
As mentioned earlier, immunoblot was one of the first at-
tempts to establish an appropriate multiplex test for the con-
firmation of ANA by using whole cell extracts with a similar
autoantigen composition of HEp-2 cells [98, 148]. However,
due to technical challenges, poor reproducibility, and loss of
the native conformational structure of the relevant
autoantigenic epitopes, this method was not established as a
standard for multiplex autoAb analysis [19, 25, 149, 150].
As a result of improved purification methods for native
autoantigens and progress in the expression of recombinant
autoantigenic targets, the use of both molecule sources did not
only enable the development of singleplex autoAb ELISAs
but of multiplex dot or line immunoassays (D/LIAs),
too [116, 140, 151]. In daily laboratory routine, D/LIAs have
been established as one of the standard tests for ANA and
ANCA confirmation [140, 152–154]. Moreover, D/LIAs ap-
pear to be an ideal solution for other serological diagnoses,
where multiple autoAbs are required [155–158]. This holds
not only true for CD serology where even a simultaneous IgA
deficiency can be conducted apart from the (auto)Ab testing
but proved to be very effective for the serology of SSc, DM/
PM, or autoimmune liver diseases [140, 154]. Thus, D/LIAs
with more than 20 autoantigenic targets have been introduced
for the confirmatory diagnostics of ANA successfully [159].
Of note, the miniaturization of the technique by deploying
sophisticated nanoliter dispensing devices and pattern recog-
nition software for optical density reading render this tech-
niquemost potential for futuremultiplex autoAb testing [160].
It should be noted in this context, that the attempts to em-
ploy the 96-well ELISA platform for autoAb multiplexing by
using single wells for the immobilization of distinct antigens
appear to be just an intermediate stage which was called into
question very soon due to obvious shortcomings of the
approach.
The progress in fluorescence reading as well as flow cy-
tometry and microscopy paved the way for a new era in
multiplexing [161–169]. Thus, several multiplex assay
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developments employing surface-activated microbeads coded
by fluorescent dyes, size, or shape on the one hand and fluo-
rescence microscopy or flow cytometry as read-out on the
other hand were reported [170–172].
The intriguing biochip mosaic technology enabled mul-
tiplex autoAb IIF reading by using various cellular and
tissue substrates on one solid phase [173–175]. Further,
the luminex technology deploying fluorescence-coded
microbeads and flow cytometry enabled the development
of an intriguing and very successful multiplex autoAb de-
tection technique [176, 177]. Very soon, this novel tech-
nology was commercialized by several companies. The
possibility to detect several autoAbs and the high through-
put led to the development of such multiplex autoAb sys-
tems like Athena and FIDIS or the fully automated
BioPlex2000 system covering various serological autoim-
mune diagnoses [172, 177–179]. The growing success and
the ready automation of the luminex technology were very
appealing especially for larger laboratories with ever grow-
ing sample volumes [177]. Indeed, demand for autoAb
testing started rising exponentially in the 1980s and this
phenomenon called into question even the recommended
two-tier strategy encompassing IIF as the ideal autoAb
screening [180–182]. As a matter of fact, laboratories in
particular in the USA have begun replacing IIF due to its
major shortcomings, namely lack of automation, standard-
ization, modern data processing, and experts in IIF reading
[3, 43, 73, 170, 183, 184]. Although the newly developed
luminex applications for autoAb testing helped to ease the
pressure in terms of rising autoAb analyses, there was
growing dissatisfaction among rheumatologists with the
assay performance of the technology [42]. Indeed, false-
negative ANA findings leading to ill-defined diagnoses
raised the concern of clinicians [185, 186]. Consequently,
the American College of Rheumatology (ACR) initiated a
task force in 2009 investigating the issue [42]. In conclu-
sion, IIF was confirmed as standard method for ANA read-
ing and laboratories requested to return to the two-stage
strategy or to make sure that clinicians requesting ANA
testing are aware of the different assay performance by
multiplexing [4].
Of note, despite the development of similar multiplex tests
for ANCA testing, IIF was also not challenged as screening
assay in the two-stage strategy yet.
Improvement of IIF by Digital Fluorescence
The decision of the ANA task force of the ACR to retain the
status of IIF and, thus, to confirm the two-stage strategy for
CTD serology required an overhaul of the IIF technique
badly [180, 181].
To employ this technique in a modern laboratory envi-
ronment for CTD-associated antibody testing, the earlier
mentioned shortcomings of IIF are needed to be ad-
dressed. In this context, the tremendous progress in fluo-
rescence microscopy, image taking, and software develop-
ment helped to usher in a new era of digital fluorescence
[56, 161, 187, 188]. To the best of our knowledge, our
group was the first to overcome critical disadvantages of
ANA reading with IIF by introducing a standardized and
automated fluorescence interpretation system which is
based on the Videoscan technology and commercialized
under the AKLIDES® brand [162, 189, 190]. AKLIDES®
enables automated IIF reading by a sequential, multistage
process including image acquisition by a CCD camera
and software-controlled quality control, object segmenta-
tion, object description, and object classification by the
use of novel pattern recognition algorithms. Thus, the
system representing a composition of different hardware
modules including a motorized inverse fluorescence
microscope enables dynamic autofocusing resulting in
the acquisition of quantitative fluorescence signals. The
ensuing increased standardization and automation diminished
the high intralaboratory and interlaboratory variability of
ANA IIF reading, allowed the differentiation of cytoplasmic
from nuclear staining, and rendered this method more
applicable to high throughput screening [191–193].
Other diagnostic companies started developing similar sys-
tems and introducing new technologies for automated IIF pat-
tern interpretation. In general, these commercially available
systems are based on digital acquisition of fluorescence sig-
nals and most of them enable automated analysis of IIF im-
ages by pattern recognition algorithms (AKLIDES®,
Medipan, Dahlewitz/Berlin, Germany; Nova View®, Inova,
San Diego, USA; Zenit G Sight, A. Menarini Diagnostics,
Grassina-Firenze, Italy; Europattern®, Euroimmun, Lübeck,
Germany) [20, 194–196]. However, few systems distinguish
between positive and negative screening results only (Helios,
Aesku.Diagnostics, Wendelsheim, Germany; Image
Navigator, Immuno Concepts, Sacramento, USA; Cytospot,
Autoimmun Diagnostika, Straßberg, Germany) [185, 197]. In
summary, all systems were reported to meet the demand for
automated interpretation and satisfactory system perfor-
mances were obtained by comparative studies at least for qual-
itative ANA evaluation [197, 198].
The fully automated interpretation systemAKLIDES®was
the first platform which performance was evaluated in clinical
studies successfully [199–201]. Egerer et al. published the
first clinical evaluation in 2010 by comparing the use of the
new technology for ANA assessment of 1222 sera in the rou-
tine laboratory environment of both a university and a private
referral laboratory [199]. An agreement of 93.0 % (859/924)
and of 90.6 % (270/298) between automated AKLIDES®
interpretation and classical ANA reading in the university
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and the private laboratory were reported, respectively.
Remarkably, end-titer analysis based on quantitative fluo-
rescence reading was shown for the first time, which over-
comes a crucial shortcoming of IIF and levels it with other
quantitative assay techniques established in routine clinical
laboratories. Thus, the application range of the novel inter-
p r e t a t i on sy s t ems (AKLIDES®, Eu ropa t t e rn® ,
NovaView®) was enlarged by adding ANCA and anti-
dsDNA autoAb testing on human neutrophils and
Crithidia luciliae, respectively [191, 202–204].
In summary, the intriguing development of these novel
automated IIF interpretation systems strengthened the position
of IIF as screening technique within the two-tier strategy for
ANA and ANCA analyses. Thus, the demand of even large
laboratories in terms of automated autoAb testing by IIF with
modern data management could be addressed adequately.
Tozzoli et al. concluded that a new technological era in
the routine autoimmune laboratory was reached by the in-
troduction of fully automated IIF in 2009 [180].
Furthermore, this technology may also stimulate clinical
research regarding larger population studies, e.g., the prev-
alence of the dense-fine speckled (DFS) pattern, and hence,
of the DFS70 autoAbs, in different apparently healthy and
diseased populations [205].
Combination of Screening andConfirmatory Testing
Irrespectively of the tremendous progress in automated
autoAb testing by IIF at the beginning of this millennium,
the constraint to use two different assay techniques for the
recommended two-stage strategy of ANA and ANCA
analyses has not been abolished yet [4]. This strategy en-
ables a plausibility control of the obtained results because
specific autoAb assays may give false-positive findings. For
instance, a positive anti-dsDNA finding in ELISA in com-
bination with ANA negativity cannot be regarded as relevant
regarding diagnosis of SLE. However, the possibility of
false-negative findings using the two-tier strategy especially
for ANA reading in terms of sera positive for autoAbs to SS
antigen A (SS-A/Ro) is still eminent at hand and represents
an essential drawback of such approach [206]. Only the
combination of both stages in one multiplex test would over-
come these shortcomings and provide an ideal solution for
autoAb testing addressing key clinical and laboratory needs.
As a fact, this intriguing idea is quite simple, and thus, it
appears astonishing that no such attempt was undertaken
earlier. Hence, combination of the advantages of cell-based
assays and the potential for multiplexing by microbead
immunoassay (MIA) employing IIF within one reaction
environment could revolutionize autoimmune diagnostics
(Fig. 2).
Second-Generation ANATesting
To realize the idea of combining autoAb screening and con-
firmation, we started developing a unique IIF reaction envi-
ronment encompassing classical ANA analysis on HEp-2
cells and simultaneous multiplex detection of autoAbs by
MIA. Indeed, merging screening and confirmatory testing
for disease-specific autoAbs could generate many benefits
including shorter hands-on times, better reproducibility of
autoAb findings, and higher cost-effectiveness especially for
larger sample series.
First, a MIA which utilizes multiple carboxylated
polymethylmethacrylate bead populations differing in size
and/or concentrations of fluorescent dye for multiplexing
was developed [207]. The classification of bead populations
and measurement of corresponding ligand fluorescence inten-
sity was readily performed by AKLIDES® enabling the de-
tection of six different antinuclear autoAbs to Scl-70, Sm, SS-
A (Ro60), SS-B (La), CENP-B, and, dsDNA. This assay
development created the basis for the design of a unique IIF
reaction environment which could integrate the classical ANA
testing on HEp-2 cells in one test [102]. The new assay tech-
nique combining classical ANA testing with confirmatory
analysis by MIA was termed CytoBead® technology
(Fig. 3a). Intriguingly, the novel options of digital fluores-
cence enabling quantitative analysis not only of specific
autoAb testing by MIA but also of classical ANA reading on
HEp-2 cells can be readily employed by CytoBead® assays.
Thus, they can be standardized by calibrated interpretation
systems for automated autoAb testing. Consequently, this is a
new age of standardization of ANA testing as a whole which
was not feasible with classical ANA testing by IIF in the past.
Altogether, a new generation of autoAb testing could be
established that can meet the demand of modern routine
service laboratories for the serology of SARD/CTD by ad-
dressing the key disadvantages of the currently recom-
mended two-stage autoAb testing.
Recently, this new assay referred to as second generation
ANA testing was evaluated in a comprehensive serological
study comprising inter alia 174 patients with SLE, 103 with
SSc, 46 with SjS, 36 with RA, 13 with MCTD, 21 with DM/
PM, 21 with infectious disease, 93 with autoimmune liver
diseases, 78 with inflammatory bowel disease, and 101
blood donors [102]. The CytoBead® ANA simultaneously
determines ANA on HEp-2 cells and autoAbs to dsDNA,
CENP-B, SS-A/Ro52, SS-A/Ro60, SS-B/La, RNP-Sm,
Sm, and Scl-70. The obtained good agreement of the
CytoBead® ANA with classical ANA reading by IIF and
ELISA supports the notion that the novel combined reac-
tion IIF environment for one-step ANA analysis employing
HEp-2 cells and autoantigen-coated fluorescent beads as
respective targets can provide at least the same assay per-
formance like classical two-tier ANA testing.
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Furthermore, simultaneous detection of ANA and specific
autoAbs such as to SS-A/Ro by CytoBead® ANA can almost
eliminate the risk of false-negative findings and increase the
already high negative predictive value of ANA testing. Of
note, this is especially in the interest of rheumatologists who
would like to exclude the presence of autoimmunity in their
differential diagnosis of SARD by ordering ANA testing. In
this study, 4/267 (1.5 %) ANA-negative patients with positive
anti-SS-A or anti-CENP-B autoAbs were determined by
second-generation ANA analysis. As a fact, these distinct
patients with RA and SjS would have been missed by the
currently recommended two-tier strategy since ANA negativ-
ity and positivity for anti-SS-A and anti-CENP-B autoAbs
were confirmed by classical testing.
New-Generation ANCATesting
The CytoBead® technology was also applied for the compre-
hensive analysis of ANCA and the resulting CytoBead®
ANCA was evaluated in terms of its assay performance
[208]. Indeed, the combination of both IIF and antigen-
specific assays was found in several studies to be the optimal
strategy for ANCA detection and led to the recommendation
of a two-stage ANCA testing.
Alike CytoBead® ANA development, after having de-
signed a multiplex addressable MIA detecting MPO-ANCA,
PR3-ANCA, and autoAbs against the noncollagen region of
the alpha-3 subunit of collagen IV representing the glomerular
basement membrane (GBM) antigen, a unique reaction envi-
ronment for the additional detection of ANCA on fixed neu-
trophils was generated (Fig. 3b). The novel CytoBead®
ANCA is a unique combination of a classical cell-based assay
with multiplexing microbead technology [204, 208].
Sowa et al. recruited 592 patients including 118 patients
with AAV, 133 with RA, 49 with infectious diseases, 77 with
inflammatory bowel disease, 20 with autoimmune liver dis-
eases, 70 with primary sclerosing cholangitis (PSC), and 125
blood donors and compared multiplex CytoBead® ANCA
testing with classical methods such as IIF and ELISA [208].
Quantitative PR3- and MPO-ANCA analysis by multiplex
CytoBead® technology turned out to be at least equal or better
compared to classical ELISA testing for specific ANCA.
Remarkably, automated endpoint ANCA titer analysis by only
one serum dilution employing the automated interpretation
system AKLIDES® revealed a very good agreement with
the classical ANCA IIF on neutrophils. Another intriguing
finding was the detection of PR3-ANCA in patients suffering
from ulcerative colitis (UC) and PSC apart from those with
GPA. These data appear to confirm a recent report of PR3-
ANCA positive patients suffering from UC and PSC de-
tected by another sensitive MIA technique [138]. Thus,
the new reaction environment of the CytoBead® ANCA
enables highly sensitive PR3-ANCA testing and might
compete with third-generation ELISA in terms of assay
performance.
Consequently, automated multiplex IIF combining screen-
ing and confirmatory ANCA testing in one test may replace
the time-consuming current two-stage ANCA testing strategy
by a one-step multiplexing CytoBead® analysis [206]. In con-
text of the emergency diagnostics required for rapidly progres-
sive glomerulonephritis, the novel multiplex ANCA analysis
by CytoBead® appears to be an attractive approach to meet
the clinical need for comprehensive ANCA testing in the
fastest way possible.
Comprehensive CD Serology
The serological diagnosis of CD comprises the detection of
EMA and auto/Abs against deamidated gliadin and TG2 of
the IgA isotype. As a fact, EmA detected by IIF is still
Fig. 2 Multiplexing strategy of CytoBead® technology exemplified for
CytoBead® ANA assay. Combination of ANA screening with HEp-2
cells (middle part) and anti-ENA testing with antigen-coated
microbeads (peripheral parts I–IV) in one reaction environment.
Example of an ANA positive serum with positive homogeneous
fluorescence pattern on HEp-2 cells and positive signal on dsDNA-
coated microbeads presented as green fluorescence halo (small red
microbeads in part III). ANA antinuclear antibody, CENP centromere
protein, Da Dalton, dsDNA double-stranded DNA, ENA extractable
nuclear antigen, hom homogeneous, RNP ribonuclear protein, Scl-70
DNA-Topoisomerase I, Sm Smith, SS Sjögren-Syndrome, (+) positive,
(−) negative
Clinic Rev Allerg Immunol
considered the gold standard for (auto)Ab testing in CD
[65]. To address the need for comprehensive CD-specific
(auto)Ab testing in terms of workload and cost reduction in
routine autoimmune laboratories, we developed a multiplex
CytoBead® CeliAK assay (Fig. 3c) [209]. Multiplex CD-
specific (auto)Ab testing might even be an attractive diag-
nostic tool in the context of the novel diagnostic criteria
published by the European Society for Paediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN)
recently [65]. These criteria obviously strengthen the role
Fig. 3 CytoBead® assays for the
detection of a antinuclear
antibodies (ANA) with
CytoBead® ANA assay, b
antineutrophil cytoplasmic
autoantibodies (ANCA) with
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of CD serology within the workup of patients with the sus-
picion of CD. Thus, CD can be diagnosed without histology
by waiving duodenal biopsy in case of anti-TG2 autoAb
IgA levels 10 times higher than the upper limit of normal
(ULN) in patients positive for HLA-DQ2 or HLA-DQ8 and
a positive response to gluten-free diet or confirmation by
EmA testing.
Hence, the novel CytoBead® CeliAK was evaluated by
investigating in total 380 patients and controls comprising
155 CD patients, 5 with IgA-deficiency, 68 with cystic
fibrosis, 59 with eye diseases, and 93 blood donors
[209] . F ind ings were compared wi th c l a s s i ca l
IgA-(auto)Ab analyses by ELISA and IIF. As a fact, the
difference between CytoBead® and classical testing was
only significant for anti-TG2 autoAb testing whereas the
eight discrepant sera with anti-TG2 autoAb positivity by
ELISA and negative levels by CytoBead® CeliAK
belonged to four CD patients and four controls.
Altogether, the CytoBead® CeliAK represents the first
multiplex quantitative IgA anti-TG2 autoAb and anti-
DG Ab multiplex assay which provides simultaneous
EmA analysis as reference method and IgA deficiency
testing. This comprehensive approach has the potential
to improve CD serology and demonstrated excellent re-
sults regarding the great number of CD patients with
anti-TG2 autoAb levels >10× ULN due to its high sensitiv-
ity. Additionally, due to the flexibility of the technique, further
autoAbs such as those to GP2 stratifying CD patients further
might be included [210, 211].
Conclusion
Hitherto, the history of autoAb testing has been characterized
by an intriguing development of several assay techniques to
keep up with the tremendous progress in the understanding of
autoimmune diseases and their appropriate diagnostics [180,
197]. Today, autoAb analysis is an integral part in the serolog-
ical diagnosis of SARD like CTD and AAVand organ-specific
autoimmune disorders [4, 26, 60]. Hence, there is no doubt
that the introduction and further evolvement of IIF as one of
the first autoAb-detecting assay techniques had and have an
essential impact on this process [162, 197]. In the history of
autoAb testing, various techniques emerged and were re-
placed by newer ones providing better assay performance
and benefits regarding higher sample throughput and stan-
dardization [34, 80]. In this context, it is astonishing to note
that IIF is still one of the key techniques to analyze autoAbs
and even recommended as screening assay within the two-
stage strategy for ANA and ANCA testing. In addition, IIF
remains a reference method for the detection of distinct
autoAbs like EmA in the serology of organ-specific autoim-
mune disorders indeed [65].
Despite the obvious benefits of IIF, this assay technique has
been characterized by time consuming and subjective evalua-
tion, insufficient automation, as well as poor standardization
since its introduction [162]. In particular, pattern reading for
ANA and ANCA testing was prone to inconsistencies in de-
scription and classification of respective staining patterns.
As a consequence, novel assay techniques based on solid-
phase immunoassays like ELISA or multiplexing technolo-
gies creating the basis for different commercial platforms
evolved and were introduced into routine autoimmune lab-
oratories [149]. Nonetheless, IIF is still recommended to be
used as the gold standard method for instance for ANA
testing due to the unsatisfactory assay performance of even
the latest multiplex technologies in this important area of
autoAb analysis [4].
This situation changed dramatically by the development of
digital fluorescence and its implementation in IIF testing. The
breathtaking new options of pattern recognition combined
with progress in automated fluorescence microscopy paved
the way for the evolvement of an entirely new generation of
automated interpretation systems [206]. Different commer-
cially available IIF platforms for autoAb testing were de-
signed and applied for ANA and ANCA reading in particular.
First evaluation studies support the good performance of these
systems and high agreement between visual and automated
autoAb interpretation [212].
Of note, this enormous technology development compris-
ing digital fluorescence image acquisition and automatic pat-
tern recognition could be extended to other cell-based IIF
assays in the search for new biomarkers. Thus, the quantifica-
tion of γH2AX foci for DNA damage analysis, which used to
be time consuming, subjective, and not suitable for high-
throughput screening, could be standardized and automated
[213, 214]. Successful evaluation studies support the introduc-
tion of this new DNA damage marker into clinical routine for
cytostatic resistance development diagnostics [215].
Nevertheless, since the majority of clinical immunology
laboratories follow the two-stage strategy for ANA and
ANCA testing, substantial constraints regarding high-
throughput and cost-effectiveness remain. The expansion of
automated IIF interpretation systems like AKLIDES® to as-
sess addressable MIAs created a unique novel assay platform
allowing fully automated evaluation of cell-based screening
tests and antigen-specific multiplex assays in one reaction
environment for the first time. The evolvement of the
CytoBead® technology combining quantitative autoAb
screening and confirmatory testing in one IIF analysis enables
second-generation autoAb detection in one test. This intrigu-
ing multiplex reaction environment addresses key needs for an
effective standardized autoAb testing in laboratory routine.
Major disadvantages of classical autoAb analysis by IIF were
overcome by this new technique. First diagnostic applications
for second-generation ANA and ANCA testing as well as
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comprehensive serology of CD-specific (auto)Abs were
developed and successfully evaluated.
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